INTRODUCTION
Total records identified through database searching (PubMed, Embase and Cochrane) N = 385
Records after duplicates removed n = 165
Articles assessed for full-text eligibility n = 55
Articles included for final review n = 8
Articles Excluded n = 47
Records excluded after abstract screening n = 110
RESULTS
Briakinumab associated with significant improvement in symptom severity compared to other treatments among patients with moderate to severe CPP.
As the reported outcomes showing wide confidence intervals, results should be interpreted with some caution.
CONCLUSION
Psoriasis is a chronic autoimmune disease characterized by formation of red, itchy, scaly patches of abnormal skin.
Psoriasis is estimated to affect 2-3% of population worldwide 
OBJECTIVE
The pathogenesis of psoriasis involves activation of T cells and cytokines; Psoriasis is now recognized as one of the most common T cell-mediated disorders 7
Antigen-induced activation of T-cells leads to initiation of cellular cascade
This leads to proliferation and differentiation of cutaneous T cells keratinocyte alterations psoriatic plaques 8
As part of this cellular cascade, many proinflammatory cytokines are released, including TNF-α and various interleukins 3
More recently, the role of the structurally related cytokines IL-12 and IL-23 in psoriasis has become apparent IL-12 and IL-23 are thought to be involved in controlling differentiation of T helper cells, during the psoriasis immune response 9
Briakinumab, a fully human anti-IL-12 ⁄23p40 monoclonal antibody, has been shown to be highly effective and well tolerated in the treatment of psoriasis in many studies Disadvantages of biologics are their high cost and strictly parenteral route of administration 1
In developed countries, biologicals are being widely used for moderate-to-severe psoriasis 1
DISCUSSION
Literature search was conducted in MEDLINE, EMBASE, Cochrane Library, and clinicaltrials.gov without any language or date restrictions
In addition, references of the included studies were screened for additional studies.
All RCTs examining the efficacy and safety of briakinumab in adult patients with moderate-to-severe chronic plaque psoriasis were included Study quality of included trials were assessed using the Cochrane Risk of Bias Tool.
Two authors independently selected papers, extracted data and assessed quality.
Our primary outcome was improvement in symptom severity assessed by Psoriasis Area Severity Index (PASI) score and Dynamic Global Physician Assessment (DGPA) score at 12 weeks.
Secondary outcomes were quality of life, assessed using Dermatology Life Quality Index (DLQI) and adverse events. 
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